
Global Intravenous Immunoglobulin (IVIg) Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Intravenous Immunoglobulin (IVIg) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Intravenous Immunoglobulin (IVIg) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Intravenous Immunoglobulin (IVIg) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Intravenous Immunoglobulin (IVIg) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Intravenous Immunoglobulin (IVIg) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Intravenous Immunoglobulin (IVIg) market include Biotest, BPL, CBPO, CNBG, CSL, Grifols, Hualan Bio, Kedrion and LFB Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Intravenous Immunoglobulin (IVIg), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Intravenous Immunoglobulin (IVIg), also provides the sales of main regions and countries. Of the upcoming market potential for Intravenous Immunoglobulin (IVIg), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Intravenous Immunoglobulin (IVIg) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Intravenous Immunoglobulin (IVIg) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Intravenous Immunoglobulin (IVIg) sales, projected growth trends, production technology, application and end-user industry.
Intravenous Immunoglobulin (IVIg) Segment by Company
Biotest
BPL
CBPO
CNBG
CSL
Grifols
Hualan Bio
Kedrion
LFB Group
Octapharma
Baxter
Shanghai RAAS
Sichuan Yuanda Shuyang
Intravenous Immunoglobulin (IVIg) Segment by Type
IVIg Liquid
IVIg Powder
Intravenous Immunoglobulin (IVIg) Segment by Application
Autoimmune Disease
Immunodeficiency
Acute Infection
Intravenous Immunoglobulin (IVIg) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Intravenous Immunoglobulin (IVIg) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Intravenous Immunoglobulin (IVIg) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Intravenous Immunoglobulin (IVIg) significant trends, drivers, influence factors in global and regions.
6. To analyze Intravenous Immunoglobulin (IVIg) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin (IVIg) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin (IVIg) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin (IVIg).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Intravenous Immunoglobulin (IVIg) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intravenous Immunoglobulin (IVIg) industry.
Chapter 3: Detailed analysis of Intravenous Immunoglobulin (IVIg) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Intravenous Immunoglobulin (IVIg) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Intravenous Immunoglobulin (IVIg) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Intravenous Immunoglobulin (IVIg) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Intravenous Immunoglobulin (IVIg) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Intravenous Immunoglobulin (IVIg) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Intravenous Immunoglobulin (IVIg) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Intravenous Immunoglobulin (IVIg) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Intravenous Immunoglobulin (IVIg) market include Biotest, BPL, CBPO, CNBG, CSL, Grifols, Hualan Bio, Kedrion and LFB Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Intravenous Immunoglobulin (IVIg), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Intravenous Immunoglobulin (IVIg), also provides the sales of main regions and countries. Of the upcoming market potential for Intravenous Immunoglobulin (IVIg), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Intravenous Immunoglobulin (IVIg) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Intravenous Immunoglobulin (IVIg) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Intravenous Immunoglobulin (IVIg) sales, projected growth trends, production technology, application and end-user industry.
Intravenous Immunoglobulin (IVIg) Segment by Company
Biotest
BPL
CBPO
CNBG
CSL
Grifols
Hualan Bio
Kedrion
LFB Group
Octapharma
Baxter
Shanghai RAAS
Sichuan Yuanda Shuyang
Intravenous Immunoglobulin (IVIg) Segment by Type
IVIg Liquid
IVIg Powder
Intravenous Immunoglobulin (IVIg) Segment by Application
Autoimmune Disease
Immunodeficiency
Acute Infection
Intravenous Immunoglobulin (IVIg) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Intravenous Immunoglobulin (IVIg) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Intravenous Immunoglobulin (IVIg) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Intravenous Immunoglobulin (IVIg) significant trends, drivers, influence factors in global and regions.
6. To analyze Intravenous Immunoglobulin (IVIg) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin (IVIg) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin (IVIg) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin (IVIg).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Intravenous Immunoglobulin (IVIg) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intravenous Immunoglobulin (IVIg) industry.
Chapter 3: Detailed analysis of Intravenous Immunoglobulin (IVIg) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Intravenous Immunoglobulin (IVIg) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Intravenous Immunoglobulin (IVIg) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
192 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Intravenous Immunoglobulin (IVIg) Sales Value (2020-2031)
- 1.2.2 Global Intravenous Immunoglobulin (IVIg) Sales Volume (2020-2031)
- 1.2.3 Global Intravenous Immunoglobulin (IVIg) Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Intravenous Immunoglobulin (IVIg) Market Dynamics
- 2.1 Intravenous Immunoglobulin (IVIg) Industry Trends
- 2.2 Intravenous Immunoglobulin (IVIg) Industry Drivers
- 2.3 Intravenous Immunoglobulin (IVIg) Industry Opportunities and Challenges
- 2.4 Intravenous Immunoglobulin (IVIg) Industry Restraints
- 3 Intravenous Immunoglobulin (IVIg) Market by Company
- 3.1 Global Intravenous Immunoglobulin (IVIg) Company Revenue Ranking in 2024
- 3.2 Global Intravenous Immunoglobulin (IVIg) Revenue by Company (2020-2025)
- 3.3 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Company (2020-2025)
- 3.4 Global Intravenous Immunoglobulin (IVIg) Average Price by Company (2020-2025)
- 3.5 Global Intravenous Immunoglobulin (IVIg) Company Ranking (2023-2025)
- 3.6 Global Intravenous Immunoglobulin (IVIg) Company Manufacturing Base and Headquarters
- 3.7 Global Intravenous Immunoglobulin (IVIg) Company Product Type and Application
- 3.8 Global Intravenous Immunoglobulin (IVIg) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Intravenous Immunoglobulin (IVIg) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Intravenous Immunoglobulin (IVIg) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Intravenous Immunoglobulin (IVIg) Market by Type
- 4.1 Intravenous Immunoglobulin (IVIg) Type Introduction
- 4.1.1 IVIg Liquid
- 4.1.2 IVIg Powder
- 4.2 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Type
- 4.2.1 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Type (2020-2031)
- 4.2.3 Global Intravenous Immunoglobulin (IVIg) Sales Volume Share by Type (2020-2031)
- 4.3 Global Intravenous Immunoglobulin (IVIg) Sales Value by Type
- 4.3.1 Global Intravenous Immunoglobulin (IVIg) Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Intravenous Immunoglobulin (IVIg) Sales Value by Type (2020-2031)
- 4.3.3 Global Intravenous Immunoglobulin (IVIg) Sales Value Share by Type (2020-2031)
- 5 Intravenous Immunoglobulin (IVIg) Market by Application
- 5.1 Intravenous Immunoglobulin (IVIg) Application Introduction
- 5.1.1 Autoimmune Disease
- 5.1.2 Immunodeficiency
- 5.1.3 Acute Infection
- 5.2 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Application
- 5.2.1 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Intravenous Immunoglobulin (IVIg) Sales Volume by Application (2020-2031)
- 5.2.3 Global Intravenous Immunoglobulin (IVIg) Sales Volume Share by Application (2020-2031)
- 5.3 Global Intravenous Immunoglobulin (IVIg) Sales Value by Application
- 5.3.1 Global Intravenous Immunoglobulin (IVIg) Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Intravenous Immunoglobulin (IVIg) Sales Value by Application (2020-2031)
- 5.3.3 Global Intravenous Immunoglobulin (IVIg) Sales Value Share by Application (2020-2031)
- 6 Intravenous Immunoglobulin (IVIg) Regional Sales and Value Analysis
- 6.1 Global Intravenous Immunoglobulin (IVIg) Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Intravenous Immunoglobulin (IVIg) Sales by Region (2020-2031)
- 6.2.1 Global Intravenous Immunoglobulin (IVIg) Sales by Region: 2020-2025
- 6.2.2 Global Intravenous Immunoglobulin (IVIg) Sales by Region (2026-2031)
- 6.3 Global Intravenous Immunoglobulin (IVIg) Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Intravenous Immunoglobulin (IVIg) Sales Value by Region (2020-2031)
- 6.4.1 Global Intravenous Immunoglobulin (IVIg) Sales Value by Region: 2020-2025
- 6.4.2 Global Intravenous Immunoglobulin (IVIg) Sales Value by Region (2026-2031)
- 6.5 Global Intravenous Immunoglobulin (IVIg) Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Intravenous Immunoglobulin (IVIg) Sales Value (2020-2031)
- 6.6.2 North America Intravenous Immunoglobulin (IVIg) Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Intravenous Immunoglobulin (IVIg) Sales Value (2020-2031)
- 6.7.2 Europe Intravenous Immunoglobulin (IVIg) Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Intravenous Immunoglobulin (IVIg) Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Intravenous Immunoglobulin (IVIg) Sales Value (2020-2031)
- 6.9.2 South America Intravenous Immunoglobulin (IVIg) Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Intravenous Immunoglobulin (IVIg) Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Intravenous Immunoglobulin (IVIg) Sales Value Share by Country, 2024 VS 2031
- 7 Intravenous Immunoglobulin (IVIg) Country-level Sales and Value Analysis
- 7.1 Global Intravenous Immunoglobulin (IVIg) Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Intravenous Immunoglobulin (IVIg) Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Intravenous Immunoglobulin (IVIg) Sales by Country (2020-2031)
- 7.3.1 Global Intravenous Immunoglobulin (IVIg) Sales by Country (2020-2025)
- 7.3.2 Global Intravenous Immunoglobulin (IVIg) Sales by Country (2026-2031)
- 7.4 Global Intravenous Immunoglobulin (IVIg) Sales Value by Country (2020-2031)
- 7.4.1 Global Intravenous Immunoglobulin (IVIg) Sales Value by Country (2020-2025)
- 7.4.2 Global Intravenous Immunoglobulin (IVIg) Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.9.2 France Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.16.2 China Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.19.2 India Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Intravenous Immunoglobulin (IVIg) Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Intravenous Immunoglobulin (IVIg) Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Intravenous Immunoglobulin (IVIg) Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Biotest
- 8.1.1 Biotest Comapny Information
- 8.1.2 Biotest Business Overview
- 8.1.3 Biotest Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Biotest Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.1.5 Biotest Recent Developments
- 8.2 BPL
- 8.2.1 BPL Comapny Information
- 8.2.2 BPL Business Overview
- 8.2.3 BPL Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.2.4 BPL Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.2.5 BPL Recent Developments
- 8.3 CBPO
- 8.3.1 CBPO Comapny Information
- 8.3.2 CBPO Business Overview
- 8.3.3 CBPO Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.3.4 CBPO Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.3.5 CBPO Recent Developments
- 8.4 CNBG
- 8.4.1 CNBG Comapny Information
- 8.4.2 CNBG Business Overview
- 8.4.3 CNBG Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.4.4 CNBG Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.4.5 CNBG Recent Developments
- 8.5 CSL
- 8.5.1 CSL Comapny Information
- 8.5.2 CSL Business Overview
- 8.5.3 CSL Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.5.4 CSL Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.5.5 CSL Recent Developments
- 8.6 Grifols
- 8.6.1 Grifols Comapny Information
- 8.6.2 Grifols Business Overview
- 8.6.3 Grifols Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Grifols Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.6.5 Grifols Recent Developments
- 8.7 Hualan Bio
- 8.7.1 Hualan Bio Comapny Information
- 8.7.2 Hualan Bio Business Overview
- 8.7.3 Hualan Bio Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Hualan Bio Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.7.5 Hualan Bio Recent Developments
- 8.8 Kedrion
- 8.8.1 Kedrion Comapny Information
- 8.8.2 Kedrion Business Overview
- 8.8.3 Kedrion Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Kedrion Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.8.5 Kedrion Recent Developments
- 8.9 LFB Group
- 8.9.1 LFB Group Comapny Information
- 8.9.2 LFB Group Business Overview
- 8.9.3 LFB Group Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.9.4 LFB Group Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.9.5 LFB Group Recent Developments
- 8.10 Octapharma
- 8.10.1 Octapharma Comapny Information
- 8.10.2 Octapharma Business Overview
- 8.10.3 Octapharma Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Octapharma Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.10.5 Octapharma Recent Developments
- 8.11 Baxter
- 8.11.1 Baxter Comapny Information
- 8.11.2 Baxter Business Overview
- 8.11.3 Baxter Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Baxter Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.11.5 Baxter Recent Developments
- 8.12 Shanghai RAAS
- 8.12.1 Shanghai RAAS Comapny Information
- 8.12.2 Shanghai RAAS Business Overview
- 8.12.3 Shanghai RAAS Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Shanghai RAAS Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.12.5 Shanghai RAAS Recent Developments
- 8.13 Sichuan Yuanda Shuyang
- 8.13.1 Sichuan Yuanda Shuyang Comapny Information
- 8.13.2 Sichuan Yuanda Shuyang Business Overview
- 8.13.3 Sichuan Yuanda Shuyang Intravenous Immunoglobulin (IVIg) Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Sichuan Yuanda Shuyang Intravenous Immunoglobulin (IVIg) Product Portfolio
- 8.13.5 Sichuan Yuanda Shuyang Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Intravenous Immunoglobulin (IVIg) Value Chain Analysis
- 9.1.1 Intravenous Immunoglobulin (IVIg) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Intravenous Immunoglobulin (IVIg) Sales Mode & Process
- 9.2 Intravenous Immunoglobulin (IVIg) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Intravenous Immunoglobulin (IVIg) Distributors
- 9.2.3 Intravenous Immunoglobulin (IVIg) Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.